Acellbia vs SAR448501

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

Acellbia

Marketed by Biocad

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02744196 · Phase 3 · completed

This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).

Reported efficacy

Percentage of patients who developed ACR20 response on 24 week of therapy (Week 24): ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%) (met)

Result source: NCT02744196

SAR448501

Developed by Sanofi

Phase 1 in Rheumatoid Arthritisbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2029 · NCT06647069 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAcellbiaSAR448501
ACR2065.7% vs 29.4%a+36.3 vs placebowk 24NCT02744196—Not reported
ACR50—Not posted · NCT02744196—Not reported
ACR70—Not posted · NCT02744196—Not reported
DAS28-CRP remission—Not posted · NCT02744196—Not reported
HAQ-DI, change—Not posted · NCT02744196—Not reported
Modified Sharp score, change—Not posted · NCT02744196—Not reported

ACR20

Acellbia
65.7% vs 29.4%a+36.3 vs placebowk 24NCT02744196
SAR448501
—Not reported

ACR50

Acellbia
—Not posted · NCT02744196
SAR448501
—Not reported

ACR70

Acellbia
—Not posted · NCT02744196
SAR448501
—Not reported

DAS28-CRP remission

Acellbia
—Not posted · NCT02744196
SAR448501
—Not reported

HAQ-DI, change

Acellbia
—Not posted · NCT02744196
SAR448501
—Not reported

Modified Sharp score, change

Acellbia
—Not posted · NCT02744196
SAR448501
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SAR448501: no structured comparison results are available for Rheumatoid Arthritis.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Acellbia

ACR20 65.7% vs 29.4% placebo @ 24wk
responder rate · % of participants
NCT02744196 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · SAR448501's landscape